人免疫球蛋白治疗重症肺炎的效果

Efficacy of Human Immunoglobulin in the Treatment of Severe Pneumonia

目的探讨人免疫球蛋白联合胸腺肽α1治疗重症肺炎的疗效。方法选取重症肺炎患者94例,随机分为观察组与对照组,各47例。对照组给予胸腺肽α1治疗,观察组在此基础上给予人免疫球蛋白治疗。比较2组患者临床疗效、血清炎性因子水平与免疫功能指标。结果治疗7 d后,观察组总有效率97.87%,高于对照组的78.72%,差异有统计学意义(P<0.05);治疗7 d后,观察组炎性因子白介素-6(IL-6)、白介素-8(IL-8)、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)水平分别为(69.44±14.39)ng/L、(41.61±12.08)ng/L、(38.64±8.52)mg/L及(148.92±20.62)ng/L,低于对照组的(105.64±18.34)ng/L、(99.36±17.25)ng/L、(53.64±10.28)mg/L及(178.64±23.58)ng/L,差异有统计学意义(P<0.05);观察组IgA、IgG、IgM、CD4+、CD4+/CD8+水平分别为(2.35±0.86)μg/L、(12.86±2.31)μg/L、(1.31±0.45)μg/L、(55.82±7.25)%及(2.82±1.15),高于对照组(1.52±0.61)μg/L、(7.85±1.98)μg/L、(1.08±0.36)μg/L、(48.63±6.58)%及(2.11±1.03),差异有统计学意义(P<0.05)。结论人免疫球蛋白联合胸腺肽α1治疗重症肺炎效果确切,可降低患者炎性因子水平,抑制炎症反应,提高免疫功能。

Objective To investigate the efficacy of human immunoglobulin combined with thymosinα1 in the treatment of severe pneumonia.Methods 94 patients with severe pneumonia were divided into observation group and control group by randomized double blind method,with 47 cases in each group.Control group was given thymosinα1,while observation group was treated with human immunoglobulin based on control group.The clinical efficacy,serum inflammatory factors,immune function indexes were compared between the two groups.Results After treatment for 7d,the total effective rate of observation group(97.87%)was higher than control group(78.72%).There was statistical significance(P<0.05).After treatment for 7d,the interleukin-6(IL-6),IL-8,C-reactive protein(CRP),tumor necrosis factorα(TNF-α)in observation group[(69.44±14.39)ng/L,(41.61±12.08)ng/L,(38.64±8.52)mg/L,(148.92±20.62)ng/L]were lower than those in control group[(105.64±18.34)ng/L,(99.36±17.25)ng/L,(53.64±10.28)mg/L,(178.64±23.58)ng/L].There was statistical significance(P<0.05).The immunoglobulin A(IgA),IgG,IgM,CD4+,CD4+/CD8+in observation group[(2.35±0.86)μg/L,(12.86±2.31)μg/mL,(1.31±0.45)μg/L,(55.82±7.25)%,(2.82±1.15)]were higher than those in control group[(1.52±0.61)μg/L,(7.85±1.98)μg/L,(1.08±0.36)μg/L,(48.63±6.58)%,(2.11±1.03)].There was statistical significance(P<0.05).Conclusion Human immunoglobulin combined with thymosinα1 in the treatment of severe pneumonia is effective.It can decrease the levels of serum inflammatory factors,inhibit inflammatory response,increase immune function.